|
|
小细胞肺癌肝转移机制及预测指标的研究进展
|
Abstract:
小细胞肺癌(Small Cell Lung Cancer, SCLC)作为一种肝癌亚型，其恶性程度高，转移早，患者预后差，对社会及患者家庭造成严重医疗负担。本文以小细胞肺癌肝转移生物基础及分子机制为视角，对小细胞肺癌肝转移的机制和预测指标的最新研究进展进行综述。与此同时，对当前关于预测SCLC肝转移的生物标志物的研究进行评估并简要概述当前治疗策略，最后对SCLC未来研究方向进行展望，目的在于为临床治疗和未来研究提供参考。
Small cell lung cancer (SCLC), as a subtype of liver cancer, has high malignant degree, early metastasis and poor prognosis, which causes serious medical burden to the society and patients’ families. From the perspective of biological basis and molecular mechanism of liver metastasis of small cell lung cancer, this paper reviews the latest research progress on the mechanism and predictive indexes of liver metastasis of small cell lung cancer. At the same time, the current research on biomarkers predicting SCLC liver metastasis was evaluated and the current treatment strategies were briefly summarized. Finally, the future research direction of SCLC was prospected, in order to provide reference for clinical treatment and future research.
| [1] | Mbijer, J.J., Leonetti, A., Airò, G., et al. (2022) Small Cell Lung Cancer: Novel Treatments beyond Immunotherapy. Seminars in Cancer Biology, 86, 376-385. https://doi.org/10.1016/j.semcancer.2022.05.004 |
| [2] | 陈东方. 广泛期小细胞肺癌基因突变与预后的关系[D]: [博士学位论文]. 上海: 上海交通大学, 2020. |
| [3] | Megyesfalvi, Z., Gay, C.M., Popper, H., et al. (2023) Clinical Insights into Small Cell Lung Cancer: Tumor Heterogeneity, Diagnosis, Therapy, and Future Directions. CA: A Cancer Journal for Clinicians, 73, 620-652. https://doi.org/10.3322/caac.21785 |
| [4] | Megyesfalvi, Z., Tallosy, B., Pipek, O., et al. (2021) The Landscape of Small Cell Lung Cancer Metastases: Organ Specificity and Timing. Thoracic Cancer, 12, 914-923. https://doi.org/10.1111/1759-7714.13854 |
| [5] | Ko, J., Winslow, M.M. and Sage, J. (2021) Mechanisms of Small Cell Lung Cancer Metastasis. EMBO Molecular Medicine, 13, e13122. https://doi.org/10.15252/emmm.202013122 |
| [6] | Xiao, Y. and Yu, D. (2021) Tumor Microenvironment as a Therapeutic Target in Cancer. Pharmacology & Therapeutics, 221, Article ID: 107753. https://doi.org/10.1016/j.pharmthera.2020.107753 |
| [7] | Vitale, I., Manic, G., Coussens, L.M., et al. (2019) Macrophages and Metabolism in the Tumor Microenvironment. Cell Metabolism, 30, 36-50. https://doi.org/10.1016/j.cmet.2019.06.001 |
| [8] | Niu, X., Chen, L., Li, Y., et al. (2022) Ferroptosis, Necroptosis, and Pyroptosis in the Tumor Microenvironment: Perspectives for Immunotherapy of SCLC. Seminars in Cancer Biology, 86, 273-285. https://doi.org/10.1016/j.semcancer.2022.03.009 |
| [9] | Li, T. and Qiao, T. (2022) Unraveling Tumor Microenvironment of Small-Cell Lung Cancer: Implications for Immunotherapy. Seminars in Cancer Biology, 86, 117-125. https://doi.org/10.1016/j.semcancer.2022.09.005 |
| [10] | Petty, W.J. and Paz-Ares, L. (2023) Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review. JAMA Oncology, 9, 419-429. https://doi.org/10.1001/jamaoncol.2022.5631 |
| [11] | Yin, X., Li, Y., Wang, H., et al. (2022) Small Cell Lung Cancer Transformation: From Pathogenesis to Treatment. Seminars in Cancer Biology, 86, 595-606. https://doi.org/10.1016/j.semcancer.2022.03.006 |
| [12] | Chan, J.M., Quintanal-Villalonga, á., Gao, V.R., et al. (2021) Signatures of Plasticity, Metastasis, and Immunosuppression in An Atlas of Human Small Cell Lung Cancer. Cancer Cell, 39, 1479-1496. https://doi.org/10.1016/j.ccell.2021.09.008 |
| [13] | Tungsukruthai, S., Sritularak, B. and Chanvorachote, P. (2017) Cycloartobiloxanthone Inhibits Migration and Invasion of Lung Cancer Cells. Anticancer Research, 37, 6311-6319. |
| [14] | Liang, H., Zhang, L., Zhao, X., et al. (2023) The Therapeutic Potential of Exosomes in Lung Cancer. Cellular Oncology, 46, 1181-1212. https://doi.org/10.1007/s13402-023-00815-8 |
| [15] | Yuan, M., Zhao, Y., Arkenau, H.T., et al. (2022) Signal Pathways and Precision Therapy of Small-Cell Lung Cancer. Signal Transduction and Targeted Therapy, 7, Article No. 187. https://doi.org/10.1038/s41392-022-01013-y |
| [16] | Marcoux, N., Gettinger, S.N., O’Kane, G., et al. (2019) EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. Journal of Clinical Oncology, 37, 278-285. https://doi.org/10.1200/JCO.18.01585 |
| [17] | Pan, J., Fang, S., Tian, H., et al. (2020) LncRNA JPX/MiR-33a-5p/Twist1 Axis Regulates Tumorigenesis and Metastasis of Lung Cancer by Activating Wnt/β-Catenin Signaling. Molecular Cancer, 19, Article No. 9. https://doi.org/10.1186/s12943-020-1133-9 |
| [18] | Li, D., Tong, Q., Lian, Y., et al. (2021) Inhibition of LncRNA KCNQ1OT1 Improves Apoptosis and Chemotherapy Drug Response in Small Cell Lung Cancer by TGF-β1 Mediated Epithelial-to-Mesenchymal Transition. Cancer Research and Treatment, 53, 1042-1056. https://doi.org/10.4143/crt.2020.1208 |
| [19] | Rudin, C.M., Brambilla, E., Faivre-Finn, C., et al. (2021) Small-Cell Lung Cancer. Nature Reviews Disease Primers, 7, Article No. 3. https://doi.org/10.1038/s41572-020-00235-0 |
| [20] | George, J., Lim, J.S., Jang, S.J., et al. (2015) Comprehensive Genomic Profiles of Small Cell Lung Cancer. Nature, 524, 47-53. https://doi.org/10.1038/nature14664 |
| [21] | Sivakumar, S., Moore, J.A., Montesion, M., et al. (2023) Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation. Cancer Discovery, 13, 1572-1591. https://doi.org/10.1158/2159-8290.CD-22-0620 |
| [22] | Febres-Aldana, C.A., Chang, J.C., Ptashkin, R., et al. (2022) Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset. Clinical Cancer Research, 28, 4702-4713. https://doi.org/10.1158/1078-0432.CCR-22-1115 |
| [23] | Ireland, A.S., Micinski, A.M., Kastner, D.W., et al. (2020) MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. Cancer Cell, 38, 60-78. https://doi.org/10.1016/j.ccell.2020.05.001 |
| [24] | Pongor, L.S., Schultz, C.W., Rinaldi, L., et al. (2023) Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes. Cancer Discovery, 13, 928-949. https://doi.org/10.1158/2159-8290.CD-22-0796 |
| [25] | Wang, L., Chen, C., Song, Z., et al. (2022) EZH2 Depletion Potentiates MYC Degradation Inhibiting Neuroblastoma and Small Cell Carcinoma Tumor Formation. Nature Communications, 13, Article No. 12. https://doi.org/10.1038/s41467-021-27609-6 |
| [26] | Yin, X., Yang, J., Wang, H., et al. (2022) Non-Coding Genome in Small Cell Lung Cancer between Theoretical View and Clinical Applications. Seminars in Cancer Biology, 86, 237-250. https://doi.org/10.1016/j.semcancer.2022.03.024 |
| [27] | Ghafouri-Fard, S., Shoorei, H., Branicki, W., et al. (2020) Non-Coding RNA Profile in Lung Cancer. Experimental and Molecular Pathology, 114, Article ID: 104411. https://doi.org/10.1016/j.yexmp.2020.104411 |
| [28] | Hamilton, G. and Rath, B. (2015) Smoking, Inflammation and Small Cell Lung Cancer: Recent Developments. Wiener Medizinische Wochenschrift, 165, 379-386. https://doi.org/10.1007/s10354-015-0381-6 |
| [29] | Rath, B., Plangger, A., Klameth, L., et al. (2023) Small Cell Lung Cancer: Circulating Tumor Cell Lines and Expression of Mediators of Angiogenesis and Coagulation. Exploration of Targeted Anti-Tumor Therapy, 4, 355-365. https://doi.org/10.37349/etat.2023.00139 |
| [30] | Zheng, Y., Wang, L., Yin, L., et al. (2022) Lung Cancer Stem Cell Markers as Therapeutic Targets: An Update on Signaling Pathways and Therapies. Frontiers in Oncolog, 12, Article 873994. https://doi.org/10.3389/fonc.2022.873994 |
| [31] | Lim, J.S., Ibaseta, A., Fischer, M.M., et al. (2017) Intratumoural Heterogeneity Generated by Notch Signalling Promotes Small-Cell Lung Cancer. Nature, 545, 360-364. https://doi.org/10.1038/nature22323 |
| [32] | Schneider, B.J. and Kalemkerian, G.P. (2016) Personalized Therapy of Small Cell Lung Cancer. In: Ahmad, A. and Gadgeel, S., Eds., Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management, Springer, Cham, 149-174. https://doi.org/10.1007/978-3-319-24932-2_9 |
| [33] | Plaja, A., Moran, T., Carcereny, E., et al. (2021) Small-Cell Lung Cancer Long-Term Survivor Patients: How to Find a Needle in a Haystack? International Journal of Molecular Sciences, 22, Article 13508. https://doi.org/10.3390/ijms222413508 |
| [34] | Khan, P., Siddiqui, J.A., Kshirsagar, P.G., et al. (2023) MicroRNA-1 Attenuates the Growth and Metastasis of Small Cell Lung Cancer through CXCR4/FOXM1/RRM2 Axis. Molecular Cancer, 22, Article No. 1. https://doi.org/10.1186/s12943-022-01695-6 |
| [35] | Pellini, B. and Chaudhuri, A.A. (2023) CtDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time? Clinical Cancer Research, 29, 2176-2178. https://doi.org/10.1158/1078-0432.CCR-23-0420 |
| [36] | Wang, Y., Zou, S., Zhao, Z., et al. (2020) New Insights into Small-Cell Lung Cancer Development and Therapy. Cell Biology International, 44, 1564-1576. https://doi.org/10.1002/cbin.11359 |
| [37] | Bogart, J.A., Waqar, S.N. and Mix, M.D. (2022) Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer. Journal of Clinical Oncology, 40, 661-670. https://doi.org/10.1200/JCO.21.01639 |
| [38] | Yang, S., Zhang, Z. and Wang, Q. (2019) Emerging Therapies for Small Cell Lung Cancer. Journal of Hematology & Oncology, 12, Article No. 47. https://doi.org/10.1186/s13045-019-0736-3 |
| [39] | Zugazagoitia, J. and Paz-Ares, L. (2022) Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options. Journal of Clinical Oncology, 40, 671-680. https://doi.org/10.1200/JCO.21.01881 |
| [40] | Wang, W.Z., Shulman, A., Amann, J.M., et al. (2022) Small Cell Lung Cancer: Subtypes and Therapeutic Implications. Seminars in Cancer Biology, 86, 543-554. https://doi.org/10.1016/j.semcancer.2022.04.001 |
